Log in to save to my catalogue
Log in to save to my catalogue

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

| Ask | Become a Library member

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1682891456

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

About this item

Publication information

Publisher

United States: Massachusetts Medical Society

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Pembrolizumab, an inhibitor of programmed cell death 1 (PD-1), produced responses in 24% of patients with non–small-cell lung cancer, with a median overall survival of 16.2 months. The response rate increased to 45% if more than 50% of tumor cells expressed the PD-1 ligand.
Lung cancer is the leading cause of cancer-related death worldwide.
1...

Alternative Titles

Full title

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Authors, Artists and Contributors

Author / Creator

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1682891456

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1682891456

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1501824

How to access this item

Log in as a Library member

Full text available

About resource

View in old catalogue

Connecting people and collections